| Latest Vertex Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 04/21/2008 | 3:12PM | PRNUS | Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Ver
BENSALEM, Pa., April 21 /PRNewswire/ -- Law Offices of Howard G. Smith announces a May 12, 2008, deadline to move to be a lead plaintiff in the securities class action lawsuit filed on behalf of all persons who purchased the publicly traded securities of Vertex Pharmaceuticals Inc. ("Vertex" or the "Company") (NASDAQ:VRTX... More...>> |
| 04/18/2008 | 6:00PM | PRNUS | Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler
RADNOR, Pa., April 18 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of all purchasers of securities of Vertex... More...>> |
| 03/20/2008 | 9:00AM | PRNUS | Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
NEW YORK, March 20 /PRNewswire/ -- Dreier LLP (http://www.dreierllp.com/) announces that a class action lawsuit was commenced in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NASDAQ:VRTX) publicly traded... More...>> |
| 03/19/2008 | 2:00PM | PRNUS | Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
BENSALEM, Pa., March 19 /PRNewswire/ -- Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of all persons who purchased the publicly traded securities of Vertex Pharmaceuticals Inc. ("Vertex" or the "Company") (NASDAQ:VRTX) between June 12, 2007 and November 2, 2007... More...>> |
| 06/15/2007 | 10:59AM | PRNUS | Seven Summits Research Releases Comments on GS, CVX, CMCSA, GILD, and VRTX
CHICAGO, June 15 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at:
http://www.go7now.com/nb/0615Z (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic... More...>> |
| 02/05/2007 | 9:15AM | PRNUS | Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
CAMBRIDGE, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference and at the BIO CEO & Investor Conference.
Ian Smith, Executive Vice President and Chief... More...>> |
| 02/02/2007 | 8:30AM | PRNUS | Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011
CAMBRIDGE, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of 5.75% Convertible Senior Subordinated Notes due 2011, in accordance with the terms of the indentures governing... More...>> |
| 02/01/2007 | 4:12PM | PRNUS | Vertex Pharmaceuticals Reports 2006 Financial Results
CAMBRIDGE, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006.
"2006 was characterized by significant progress across our business, and in particular by advances in the clinical program... More...>> |
| 01/24/2007 | 9:15AM | PRNUS | Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference
CAMBRIDGE, Mass., Jan. 24 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it will webcast its corporate presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference. The presentation will be delivered by John Alam, M.D., Vertex's Executive Vice President... More...>> |
| 01/16/2007 | 9:15AM | PRNUS | Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2006 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Jan. 16 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will announce its fourth quarter and full year 2006 financial results on Thursday, February 1, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
The conference call... More...>> |
| 01/08/2007 | 8:30AM | PRNUS | Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference
-- PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950)--
CAMBRIDGE, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced its key business objectives for 2007 and provided an overview of recent developments, including highlights from research and... More...>> |
| 01/03/2007 | 4:05PM | PRNUS | Vertex Pharmaceuticals Announces Webcast of Its Presentation at the 25th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 3 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it will webcast its corporate presentation at the 25th Annual JPMorgan Healthcare Conference in San Francisco, California. Joshua Boger, Ph.D., Vertex's President and Chief Executive Officer, will... More...>> |
| 01/03/2007 | 4:05PM | PRNUS | Vertex Pharmaceuticals Announces Webcast of Its Presentation at the 25th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 3 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it will webcast its corporate presentation at the 25th Annual JPMorgan Healthcare Conference in San Francisco, California. Joshua Boger, Ph.D., Vertex's President and Chief Executive Officer, will... More...>> |
| 12/21/2006 | 8:30AM | PRNUS | Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) i
- Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing -
WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., Dec. 21
/PRNewswire-FirstCall/ -- Merck & Co., Inc. (NYSE:MRK) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the start of an international clinical trial of MK-0457 (also... More...>> |
| 12/21/2006 | 8:30AM | PRNUS | Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) i
- Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing -
WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., Dec. 21
/PRNewswire-FirstCall/ -- Merck & Co., Inc. (NYSE:MRK) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the start of an international clinical trial of MK-0457 (also... More...>> |
| 12/13/2006 | 6:55AM | PRNUS | Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investi
CAMBRIDGE, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced results from a planned interim safety analysis from PROVE 1, an ongoing Phase 2b clinical trial of the investigational hepatitis C virus (HCV) protease inhibitor telaprevir (VX-950):
* In the telaprevir... More...>> |
| 12/11/2006 | 7:40AM | PRNUS | Vertex Pharmaceuticals Added to NASDAQ-100 Index
CAMBRIDGE, Mass., Dec. 11 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006. Shares of Vertex will also be included in the NASDAQ-100 Index Tracking Stock(R... More...>> |
| 12/11/2006 | 7:31AM | PRNUS | Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity
- Additional Preclinical Combination Studies Suggest Synergistic Activity of MK-0457 and Other Kinase Inhibitors -
WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., Dec. 11
/PRNewswire-FirstCall/ -- Merck & Co., Inc. (NYSE:MRK) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced results of a Phase I clinical... More...>> |
| 11/09/2006 | 4:05PM | PRNUS | Vertex Pharmaceuticals Announces Webcasts of its Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it will webcast its presentations at the JPMorgan Small/Mid Cap Conference on Monday, November 13, 2006 at 10:15 a.m. EST; the Credit Suisse Phoenix Healthcare Conference on Thursday, November 16... More...>> |
| 11/09/2006 | 4:05PM | PRNUS | Vertex Pharmaceuticals Announces Webcasts of its Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that it will webcast its presentations at the JPMorgan Small/Mid Cap Conference on Monday, November 13, 2006 at 10:15 a.m. EST; the Credit Suisse Phoenix Healthcare Conference on Thursday, November 16... More...>> |